CINECA IRIS Institutional Research Information System

MARMORINO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.350
AS - Asia 2.018
EU - Europa 1.531
SA - Sud America 360
AF - Africa 123
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.386
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.259
SG - Singapore 732
IT - Italia 642
CN - Cina 489
HK - Hong Kong 391
BR - Brasile 291
DE - Germania 176
SE - Svezia 144
GB - Regno Unito 137
VN - Vietnam 124
BG - Bulgaria 93
FR - Francia 75
FI - Finlandia 55
CI - Costa d'Avorio 53
CA - Canada 52
RU - Federazione Russa 49
IN - India 47
NL - Olanda 42
JP - Giappone 32
KR - Corea 32
TR - Turchia 31
AT - Austria 30
ID - Indonesia 29
PL - Polonia 29
AR - Argentina 25
MX - Messico 24
BD - Bangladesh 22
NG - Nigeria 19
SN - Senegal 16
UA - Ucraina 13
IQ - Iraq 11
ES - Italia 10
VE - Venezuela 10
ZA - Sudafrica 10
PK - Pakistan 9
SA - Arabia Saudita 9
CL - Cile 8
EC - Ecuador 7
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
CO - Colombia 5
CZ - Repubblica Ceca 5
IL - Israele 5
PE - Perù 5
PT - Portogallo 5
UZ - Uzbekistan 5
BE - Belgio 4
LB - Libano 4
LT - Lituania 4
MA - Marocco 4
OM - Oman 4
PY - Paraguay 4
TH - Thailandia 4
UY - Uruguay 4
AO - Angola 3
AU - Australia 3
EG - Egitto 3
KH - Cambogia 3
PA - Panama 3
PH - Filippine 3
PS - Palestinian Territory 3
QA - Qatar 3
TN - Tunisia 3
TW - Taiwan 3
BF - Burkina Faso 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
TM - Turkmenistan 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
IE - Irlanda 1
IR - Iran 1
JO - Giordania 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MT - Malta 1
NA - Namibia 1
PR - Porto Rico 1
Totale 7.381
Salva come PNG Salva come JPEG
Città #
Ashburn 407
Hong Kong 385
Singapore 382
Woodbridge 294
Santa Clara 291
Fairfield 286
Dallas 224
Chandler 196
Shanghai 142
Seattle 125
Houston 109
New York 109
Ann Arbor 108
Cambridge 102
Wilmington 100
Sofia 93
Beijing 75
Boardman 75
Pisa 75
Florence 66
London 66
Milan 63
Los Angeles 62
Abidjan 53
Hefei 52
Munich 52
Princeton 47
Lawrence 44
Medford 38
Ho Chi Minh City 37
Seoul 32
Rome 31
Serra 31
Genoa 28
Warsaw 28
Ottawa 26
Bremen 25
Redondo Beach 25
São Paulo 25
Tokyo 25
Dearborn 23
Turku 23
Buffalo 22
Frankfurt am Main 22
Des Moines 21
Helsinki 21
Turin 20
Vienna 20
Istanbul 19
Lagos 19
Ogden 18
San Jose 18
Seacroft 18
Cascina 17
Dakar 16
Naples 16
Düsseldorf 15
Lancaster 15
San Diego 14
Nanjing 12
Phoenix 12
Fuzhou 11
Hanoi 11
Nuremberg 11
Boulder 10
Dong Ket 10
Jakarta 10
Dhaka 8
Montreal 8
Orem 8
Redwood City 8
Bandung 7
Chicago 7
Denver 7
Gargallo 7
Hyderabad 7
Marseille 7
Mumbai 7
San Francisco 7
Toronto 7
Carrara 6
Johannesburg 6
Lucca 6
Quanzhou 6
Atlanta 5
Baghdad 5
Bari 5
Boston 5
Brasília 5
Curitiba 5
Da Nang 5
Kent 5
Kunming 5
Manaus 5
Osaka 5
Pistoia 5
Poplar 5
Pune 5
Stockholm 5
Tashkent 5
Totale 5.077
Salva come PNG Salva come JPEG
Nome #
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 198
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 189
TAS-102 for the treatment of metastatic colorectal cancer 173
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients 172
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 169
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 163
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 159
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 159
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 149
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 148
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 146
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 145
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 141
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 138
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 137
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 136
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 135
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 134
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 134
null 129
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 127
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences 126
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 124
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 123
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 123
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial 123
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 121
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 121
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 118
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 118
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 111
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 109
null 109
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 109
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 107
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 105
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 102
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 98
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 97
null 91
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 91
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 90
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 88
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 87
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 83
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 80
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 73
Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application 71
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 64
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon 61
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers 56
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 53
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome 52
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer 51
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 45
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 44
Acyl-CoA binding protein for the experimental treatment of anorexia 44
null 44
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 44
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 35
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 21
null 15
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 9
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 9
Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm 4
Totale 7.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.316
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.316
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021224 0 0 0 0 0 0 33 26 54 25 24 62
2021/2022427 10 11 10 11 65 64 7 19 28 42 35 125
2022/2023763 69 115 45 55 73 90 18 45 148 5 86 14
2023/2024716 49 61 105 65 75 107 66 28 20 27 58 55
2024/20252.273 76 70 69 108 204 231 181 112 199 269 237 517
2025/20261.715 222 313 300 318 337 210 15 0 0 0 0 0
Totale 7.574